Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Comment by hmmmmmmmmon Apr 10, 2023 3:06pm
114 Views
Post# 35387151

RE:I thought…

RE:I thought…The problem is, Kellum told us all on multiple occasions about how flu season was going to increase Tigris enrollment. On multiplce occasions he told us the start date for the DIMI trial.. They talked about DIMI and SAMI as "disruptive technology" only to 180 on that. His "Worst Case" enrollment numbers?  Dead wrong.

How many times can he be wrong on the company's most important issues and still be believed?

Not to mention Kellum's 30% qoute which is hard to read as anything but disingenuous..


"Specifically, we added approximately 30% of our total enrollment target in the second half of 2022 alone"
<< Previous
Bullboard Posts
Next >>